CNB Bank Sells 771 Shares of Charles River Laboratories International, Inc. $CRL

CNB Bank lessened its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 42.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,042 shares of the medical research company’s stock after selling 771 shares during the period. CNB Bank’s holdings in Charles River Laboratories International were worth $158,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in CRL. Teacher Retirement System of Texas acquired a new position in shares of Charles River Laboratories International in the first quarter worth approximately $1,231,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Charles River Laboratories International by 15.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,118 shares of the medical research company’s stock worth $952,000 after purchasing an additional 817 shares during the period. GAMMA Investing LLC boosted its stake in shares of Charles River Laboratories International by 61.6% in the 1st quarter. GAMMA Investing LLC now owns 1,398 shares of the medical research company’s stock valued at $210,000 after purchasing an additional 533 shares during the last quarter. Concurrent Investment Advisors LLC acquired a new stake in shares of Charles River Laboratories International during the first quarter worth $213,000. Finally, GW&K Investment Management LLC raised its stake in Charles River Laboratories International by 41.1% during the first quarter. GW&K Investment Management LLC now owns 88,410 shares of the medical research company’s stock worth $13,307,000 after buying an additional 25,744 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have commented on CRL. William Blair raised shares of Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a research report on Monday, October 6th. Wall Street Zen cut Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Mizuho boosted their price target on Charles River Laboratories International from $155.00 to $174.00 and gave the company a “neutral” rating in a research note on Friday, October 17th. JPMorgan Chase & Co. raised their price objective on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the stock a “neutral” rating in a research report on Thursday, August 7th. Finally, Jefferies Financial Group upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and lifted their price objective for the company from $142.00 to $195.00 in a research note on Tuesday, September 9th. Eight research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $181.29.

Charles River Laboratories International Price Performance

Shares of CRL opened at $197.52 on Friday. The business’s fifty day moving average is $164.43 and its 200 day moving average is $150.30. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $230.02. The company has a quick ratio of 1.10, a current ratio of 1.36 and a debt-to-equity ratio of 0.69. The stock has a market cap of $9.72 billion, a P/E ratio of -148.51, a P/E/G ratio of 5.28 and a beta of 1.50.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.62. The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $983.76 million. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The business’s revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.80 earnings per share. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 800 shares of Charles River Laboratories International stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $157.60, for a total transaction of $126,080.00. Following the completion of the transaction, the executive vice president owned 24,116 shares in the company, valued at approximately $3,800,681.60. The trade was a 3.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).